Photo by nci from unsplash
Venetoclax combined with hypomethylating agents is a new therapeutic strategy frequently used for treating AML patients who are not eligible for conventional chemotherapy. However, high response rates are heterogeneous due… Click to show full abstract
Venetoclax combined with hypomethylating agents is a new therapeutic strategy frequently used for treating AML patients who are not eligible for conventional chemotherapy. However, high response rates are heterogeneous due to different mechanisms mediating resistance to venetoclax such as up‐regulation of MCL‐1 expression. We thus tested the anti‐leukemic activity of S63845, a specific MCL‐1 inhibitor.
Keywords:
inhibition venetoclax;
improves therapeutic;
venetoclax;
mcl inhibition;
pairing mcl;
venetoclax improves
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!